Long-term open-label study of tanezumab for moderate to severe osteoarthritic knee pain  T.J. Schnitzer, N.E. Lane, C. Birbara, M.D. Smith, S.L. Simpson, M.T. Brown  Osteoarthritis and Cartilage  Volume 19, Issue 6, Pages 639-646 (June 2011) DOI: 10.1016/j.joca.2011.01.009 Copyright © 2011 Osteoarthritis Research Society International Terms and Conditions

Fig. 1 Patient disposition. Osteoarthritis and Cartilage 2011 19, 639-646DOI: (10.1016/j.joca.2011.01.009) Copyright © 2011 Osteoarthritis Research Society International Terms and Conditions

Fig. 2 Onset and offset of 20 AEs of abnormal peripheral sensation experienced by 18 patients in Study 1009. ∗One patient experienced one event of hypoesthesia and one event of paresthesia; †one patient experienced two paresthesia events; ‡this event was the only AE of abnormal peripheral sensation rated as severe, all others were mild. Onset and offset of AEs of abnormal peripheral sensation are denoted by hatched bars (resolved AE) or arrows (continuing AE). Patient time in the study is depicted by the dashed line. Osteoarthritis and Cartilage 2011 19, 639-646DOI: (10.1016/j.joca.2011.01.009) Copyright © 2011 Osteoarthritis Research Society International Terms and Conditions

Fig. 3 Mean (±S.E.M.) change from 1008 baseline in weekly overall OA knee pain intensity in index knee for all patients in the ITT population reporting within 70 days of last dose. All patients received IV infusions of 50μg/kg tanezumab upon rollover from Study 1008. Arrows depict when tanezumab was administered (8-week intervals; two infusions in Study 1008; one to eight infusions in Study 1009); vertical bars are ±S.E.M. change. Osteoarthritis and Cartilage 2011 19, 639-646DOI: (10.1016/j.joca.2011.01.009) Copyright © 2011 Osteoarthritis Research Society International Terms and Conditions